Phaseline

Companies › ReproNovo Aps

ReproNovo Aps: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Leflutrozole, Dose 1
Aromatase inhibitor
CYP19A1Phase 2Semen QualityNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06993155Leflutrozole, Dose 1Phase 2Semen QualityOtherNov 2026

Targets

CYP19A1 (1)

Companies with the same targets

Rovi Pharmaceuticals Laboratories

Companies built like this

Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.